Efficacy of osimertinib in egfr-mutated advanced non-small-cell lung cancer with different t790m status following resistance to prior egfr-tkis: a systematic review and meta-analysis

HIGHLIGHTS

• who: Xiao-Fang Yi from the Scientific Institute of Romagna for the (IRCCS), Italy Department of, Shengjing Hospital of China Medical University, Shenyang, China have published the research: Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis, in the Journal: (JOURNAL) of October/26,/2021
• what: The major reason is that there are few studies assessing the efficacy of osimertinib in advanced NSCLC patients with T790M-negative or T790M-unknown statuses.
• how: This result . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.